Robust Bayesian sample size determination for avoiding the range of equivalence in clinical trials
From MaRDI portal
Publication:2480014
DOI10.1016/J.JSPI.2007.05.041zbMath1131.62019OpenAlexW2049166790MaRDI QIDQ2480014
Pierpaolo Brutti, Fulvio De Santis
Publication date: 28 March 2008
Published in: Journal of Statistical Planning and Inference (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1016/j.jspi.2007.05.041
Applications of statistics to biology and medical sciences; meta analysis (62P10) Bayesian inference (62F15) Robustness and adaptive procedures (parametric inference) (62F35)
Related Items (8)
A note on the progressive overlap of two alternative Bayesian intervals ⋮ Joint control of consensus and evidence in Bayesian design of clinical trials ⋮ Robust Bayesian monitoring of sequential trials ⋮ Bayesian Hypothesis Testing in Two‐Arm Trials with Dichotomous Outcomes ⋮ Case-Control Studies of Gene-Environment Interaction: Bayesian Design and Analysis ⋮ Bayesian-frequentist sample size determination: a game of two priors ⋮ A BAYESIAN METHOD FOR THE CHOICE OF THE SAMPLE SIZE IN EQUIVALENCE TRIALS ⋮ Predictive control of posterior robustness for sample size choice in a Bernoulli model
Cites Work
- Unnamed Item
- Robust Bayesian experimental designs in normal linear models
- Uniform and subuniform posterior robustness: The sample size problem. (With discussion)
- Robust Bayesian analysis: sensitivity to the prior
- A simulation-based approach to Bayesian sample size determination for performance under a given model and for separating models
- Closed form expressions for Bayesian sample size
- Optimal Experimental Design for Another's Analysis
- A Reference Bayesian Test for Nested Hypotheses and its Relationship to the Schwarz Criterion
- Design of Experiment for Bioassay
- Bayesian Robustness
- Robust Bayesian Analysis in Medical and Epidemiological Settings
- Sample Size Determination for Robust Bayesian Analysis
This page was built for publication: Robust Bayesian sample size determination for avoiding the range of equivalence in clinical trials